Pfizer, one of the largest drug firms in the world, has admitted to have made a major blunder lately. For the same reason, they have had to call back about a million birth control tablets. This is because there has been an error due to which the drugs have got mixed in their packaging.

In a recent study, the Food and Drug Administration has given green signal to a drug which can cure cystic fibrosis. However, the drug, Kalydeco, from Vertex Pharmaceuticals Inc., would not be that easy to get as it may cost one to shell out as much as $294,000 a year.

It has been recently revealed in a report that the new drug developed by Amylin Pharmaceutical Company from San Diego has been given approval by the Food and Drug Administration in the U. S.

It has been further revealed that with the mere decision of the approval being out, the shares of the firm have seen a rise of 17% recently.

Marking a grand success for the drugmaker Pfizer, its medicine Inlyta for patients suffering from advanced stages of kidney cancer has reportedly bagged a green light from the drug regulators in the United States, thereby marking a significant escalation in the efforts being made by the drug manufacturer with the intent of offsetting the sales of Lipitor.

It was recently revealed by the firm Genzyme Corp, which is the Cambridge segment of the French firm Sanofi, that their drug Fabrazyme has been approved by the FDA for starting production again. The firm recently said that this new drug, which is meant for the cure of Fabry disease, has been approved for production by the Food and Drug Administration in the United States.

After coming across few death cases due to Novartis AG's multiple-sclerosis drug Gilenya, the European Medical Agency (EMA) has started an investigation which would see its pros and cons. The EMA said that the main reason to conduct the review is to make sure that the drug is safe.

It has been recently revealed that the drug for diabetes which was under trial by the FDA is not passed for authenticity for now. They are of the view that there is need for more research and data on the drug, before they can approve it. The name of the drug is dapagliflozin and the FDA is of the view that there is need to prove its worth according to safety, before it can be approved.

A recent research, which was carried out by a team of researchers from the University of California, Roche and Daiichi Sankyo's Plexxikon, has revealed that Roche Holding's pill Zelboraf taken frequently by melanoma patients can result in imparting high risk of developing a rare and less harmful type of skin cancer, dubbed cutaneous squamous cell carcinoma.

It has been recently revealed that the drug firms, Mediation and Pfizer, have called it quits in the clinical testing for the drug dimebon. This was the crucial testing stage for the drug, and the firms deeming it useless, have done away with it.

Recent reports have found that a first-line treatment for ovarian cancer, known as Roche's Avastin, is now available in the United Kingdom. The drug would act as a standard treatment in combination with the chemotherapy and surgery.